AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025
Shots:
- AstraZeneca to present Tagrisso’s data from P-III (LAURA & FLAURA2) & P-II (SAVANNAH & ORCHARD) trials at ELCC 2025 for EGFRm NSCLC pts who failed or received 1L therapy; data to support global filings
- In LAURA, Tagrisso showed favorable OS trend (mOS: 58.8 vs 54.1mos.; maturity: 31%) despite 78% of PBO pts receiving it post-progression while in SAVANNAH, Tagrisso + Orpathys achieved 56% ORR, 7.1mos. mDoR, & 7.4mos. mPFS
- In ORCHARD, Tagrisso + Datroway (6mg/kg) had 36% ORR vs 43% with 4mg/kg but showed better PFS (11.7 vs 9.5mos.) & durability (64% vs 15% at 9mos.); Datroway ± Tagrisso is also in P-III (TROPION-Lung14 & 15) trial for EGFRm NSCLC. In FLAURA2, mPFS exceeded 2yrs.; OS remain immature
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Collaborates with Syneron Bio to Develop Macrocyclic Peptides for Chronic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
